Cargando…
EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS
Prognosis for pediatric patients with advanced relapsed/refractory (R/R) solid (including central nervous system [CNS]) tumors is poor; targeted therapies achieve response rates of only ~15%. Germ cell tumors and high-grade glioma (HGG) are the most common with KIT mutations; sarcoma and HGG are the...
Autores principales: | Chi, Susan, Hsieh, Antony, Foley, Megan, Shi, Hongliang, Swamy, Preethi, Rodstrom, Jill, Rudoltz, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263205/ http://dx.doi.org/10.1093/neuonc/noab090.191 |
Ejemplares similares
-
EPCT-09. CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES
por: Puccetti, Diane, et al.
Publicado: (2020) -
EPCT-08. TRIAL WORKING GROUPS FOR PAEDIATRIC BRAIN TUMOURS
por: Rahman, Ruman, et al.
Publicado: (2021) -
EPCT-17. DEVELOPING EYA PHOSPHATASE INHIBITORS WITH ON-TARGET EFFECTS IN SHH-MEDULLOBLASTOMA
por: H. Hwang, Grace, et al.
Publicado: (2021) -
EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM
por: Ecker, Jonas, et al.
Publicado: (2021) -
EPCT-20. TECHNICAL FEASIBILITY SODIUM (23NA) MRI OF PEDIATRIC GLIOMAS
por: Bhatia, Aashim
Publicado: (2021)